Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

Source :: Plus Company Updates. December 2, 2022
Publication Year :: 2022
Abstract: New York: VALNEVA has issued the following news release: Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today reported antibody persistence data six months after the [...]

Subjects :: Pfizer Inc. -- Reports
Valneva SE -- Reports
Euronext Paris S.A. -- Reports
Vaccination -- Reports
Pediatrics -- Reports
Biotechnology industry -- Reports
Vaccines -- Reports
Lyme disease -- Reports
Securities industry -- Reports
Pharmaceutical industry -- Reports
Securities industry
General interest
News, opinion and commentary

Tools